Melanoma mutation likes fat for fuel

January 12, 2017

Cancer cells love glucose, the simple sugar the body uses for energy, so a high-fat, low-carb diet should starve them, right?

Not so fast. Research in mice suggests that melanomas and other cancers driven by a particular mutation (BRAF V600E) will grow faster in response to a high-fat diet. In addition, lipid-lowering agents such as statins curb these cancers' growth, even in the context of a more normal diet.

The results are scheduled for publication in Cell Metabolism.

While the findings cover only one mutation and need to be tested clinically, they sketch out the concept of a "precision diet," tailored to an individual patient's cancer.

"While human cancers share some common metabolic properties, they may also have distinct sensitivities depending on their oncogenic mutation profiles," says senior author Jing Chen, PhD, professor of hematology and medical oncology at Winship Cancer Institute of Emory University. "For certain mutations, it could be possible to design dietary regimens that may prevent or delay tumor progression."

Most cancer cells display enhanced glucose uptake, a phenomenon known as the Warburg effect. A low-carb diet has been tried as a clinical countermeasure in a limited way, mainly in brain cancer. In contrast, a possible implication of the Winship researchers' results is that people fighting a cancer with a BRAF V600E mutation should avoid low-carb diets.

This mutation is found in more than 60 percent of melanomas and all of the hairy cell type of leukemia, as well as a subset of colorectal cancers (10 percent) and multiple myelomas (5 percent). Drugs are available that target the BRAF V600E mutation, but resistance to the drug usually develops.

Chen's lab, working with Sumin Kang, PhD and colleagues at Winship, had previously discovered that the V600E mutation rewires cancer cells' metabolism, stimulating the ketogenesis pathway. Through ketogenesis, the body breaks down fats for energy when glucose levels in the blood are low.

One of the alternative energy sources produced by ketogenesis is acetoacetate. Within cancer cells with the V600E mutation, acetoacetate production is stimulated, the Winship researchers had found. On top of that, acetoacetate binds the mutated B-raf protein and promotes its oncogenic activity, forming a cycle of positive feedback.

The Winship researchers wanted to test whether V600E cancer cells would respond to external acetoacetate. A ketogenic diet with very low carbohydrates, like an Atkins diet, can cause acetoacetate levels in the body to rise. Fasting can also trigger the same effect.

When researchers fed mice a diet with more than 90 percent of its calories from fat, grafted tumors derived from V600E melanoma cells grew faster (twice as large over four weeks) than in mice fed a normal diet. This was not true of tumors derived from melanoma cells with other oncogenic mutations.

Lipid-lowering agents commonly used to treat high cholesterol, such as statins (in this case, fluvastatin), niacin and fenofibrate, could slow the expansion of V600E tumors in mice, even when they were fed a normal diet. Those drugs reduced acetoacetate levels, and when the researchers injected acetoacetate to compensate, tumor growth sped up again.

"Limiting dietary fat intake and monitoring circulating acetoacetate levels might be beneficial in patients with BRAF V600E melanoma or other related cancers," Chen says. "At this point, we can't be specific about diet suggestions, because we need to know more about what types of dietary fat trigger acetoacetate production."

"Lipid lowering agents may have a role in cancer prevention or supplemental treatment approaches to reduce cancer progression or improve clinical outcomes in the BRAF V600E-positive pre-malignancy and cancer settings," Chen adds.

The researchers showed that a chemical that structurally resembles acetoacetate, dehydroacetic acid, inhibits acetoacetate's effects on V600E tumor growth. Dehydroacetic acid is used in cosmetics and appears to have low toxicity, but clinical studies would be needed to assess its anticancer properties, especially at the levels that could alter cell metabolism.
-end-
Chen and colleagues at Winship Cancer Institute are planning a clinical study examining diet and acetoacetate in patients with BRAF V600E-positive cancers.

The first author of the paper is postdoctoral fellow Siyuan Xia, PhD. Jun Fan, PhD, assistant professor of radiation oncology at Winship Cancer Institute and Qun-Ying Lei, PhD at Fudan University in China were co-senior authors that contributed to design and development of the studies.

The research was supported by the National Cancer Institute (CA140515, CA183594, CA174786, CA175316), the Joel A. Katz Music Medicine Fund, the T.J. Martell Foundation, the Melanoma Research Foundation, Charles Harris Run for Leukemia, the Jamie Rabinowitch Davis Foundation and a Winship Cancer Institute pilot grant.

Emory Health Sciences

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.